Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF CATEGORY 1 INNOVATIVE DRUG BENMELSTOBART INJECTION "BENMELSTOBART (TQB2450)" IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR THE INDICATION OF FIRST-LINE TREATMENT FOR SMALL CELL LUNG CANCER2024.05.09
-
IMPLEMENTATION OF SHARE INCENTIVE SCHEME BY CHIA TAI TIANQING2024.05.07
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 20242024.05.06
-
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF CATEGORY 1 INNVOATIVE DRUG UNECRITNIB FUMARATE CAPSULES "UNECRITINIB (TQ-B3101)"2024.04.30
-
FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING (OR ANY ADJOURNMENT THEREOF)2024.04.29
-
NOTICE OF ANNUAL GENERAL MEETING2024.04.29
-
GENERAL MANDATES TO ISSUE AND BUY BACK SHARES; RE-ELECTION OF DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING2024.04.29
-
2023 ANNUAL REPORT2024.04.29